Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733546 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by COMPASS Pathways.
- Active
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 5
- Study locations
NCT05733546 is a Phase 2 study of Major Depressive Disorder that is active but no longer recruiting, run by COMPASS Pathways. The registered enrollment target is 102 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (73% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05733546, a Phase 2 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by COMPASS Pathways.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 5
- Study locations
Study Summary
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (5)
California
- Kadima Neuropsychiatry Institute - La Jolla
Florida
- Clinical Neuroscience Solutions Inc - Jacksonville
Maryland
- Sunstone Therapies - Rockville
Massachusetts
- Elixia MA, LLC - Springfield
Texas
- Aims Trial - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733546
The ClinicalTrials.gov registry entry for NCT05733546 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (73% lower). The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05733546 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT05733546 about?
NCT05733546 is a clinical study titled "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder". Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
What is the current status of trial NCT05733546?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2023-01-30. Estimated completion is 2025-09.
What conditions does trial NCT05733546 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05733546?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05733546?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733546 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.